Maplight Therapeutics (NASDAQ:MPLT – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity Group in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 target price on the stock. Canaccord Genuity Group‘s price objective would suggest a potential upside of 214.84% from the stock’s current price.
Other equities analysts have also recently issued reports about the company. BMO Capital Markets assumed coverage on Maplight Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $46.00 price target on the stock. Jefferies Financial Group restated a “buy” rating on shares of Maplight Therapeutics in a report on Monday, July 27th. Morgan Stanley cut Maplight Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $34.00 to $21.00 in a research note on Tuesday, July 28th. Wolfe Research reaffirmed an “outperform” rating and set a $30.00 target price on shares of Maplight Therapeutics in a research note on Monday, July 27th. Finally, Weiss Ratings lowered Maplight Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 23rd. Four analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.50.
Read Our Latest Report on Maplight Therapeutics
Maplight Therapeutics Price Performance
Shares of NASDAQ MPLT traded down $0.23 during mid-day trading on Tuesday, reaching $6.67. 46,014 shares of the company traded hands, compared to its average volume of 458,619. Maplight Therapeutics has a fifty-two week low of $6.06 and a fifty-two week high of $40.43. The firm has a market cap of $370.72 million and a PE ratio of -0.16. The stock has a fifty day simple moving average of $9.20 and a 200-day simple moving average of $19.79.
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.25. As a group, analysts predict that Maplight Therapeutics will post -5.01 EPS for the current fiscal year.
Insider Activity at Maplight Therapeutics
In other Maplight Therapeutics news, insider Erin Pennock Foff sold 15,355 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $8.08, for a total transaction of $124,068.40. Following the completion of the sale, the insider directly owned 296,906 shares of the company’s stock, valued at approximately $2,399,000.48. This represents a 4.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Christopher Kroeger sold 73,691 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8.08, for a total transaction of $595,423.28. Following the completion of the transaction, the chief executive officer owned 1,195,909 shares of the company’s stock, valued at approximately $9,662,944.72. The trade was a 5.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 122,974 shares of company stock valued at $990,690. Corporate insiders own 3.80% of the company’s stock.
Institutional Trading of Maplight Therapeutics
A number of hedge funds have recently modified their holdings of MPLT. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics during the second quarter valued at $34,809,708. BlackRock Inc. acquired a new stake in Maplight Therapeutics during the 2nd quarter worth about $36,741,000. Blue Owl Capital Holdings LP acquired a new stake in Maplight Therapeutics during the 2nd quarter worth about $26,161,000. ADAR1 Capital Management LLC purchased a new position in Maplight Therapeutics during the 1st quarter valued at about $7,622,000. Finally, 5AM Venture Management LLC purchased a new position in Maplight Therapeutics during the 2nd quarter valued at about $34,048,394.
Maplight Therapeutics Company Profile
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.
Further Reading
- Five stocks we like better than Maplight Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
